Neuro-Oncology Reviews
Volume
27 Number 33
30 November 2025
Home > Publications > Neuro-Oncology Reviews > Volume 27, Year 2025 > Number 33, 30 November
Antoni D, Mesny E, El Kabbaj O, Robert C, Quintin K, Feuvret L,
Biau J, Jacob J.
Radiotherapy
guidelines for gliomas: 2025 update.
Cancer
Radiother. 2025 Nov 21;29(7-8):104774. doi:
10.1016/j.canrad.2025.104774. PMID:
41273888. Guidelines. ˍ
Bell MS, Walton CM, Williams MJ, Eckert T, Brown JC, Rowland NC,
Sahin O, Strickland BA.
Engineering
focused ultrasound for glioblastoma.
Brain
Stimul. 2025 Nov 21;19(1):102986. doi:
10.1016/j.brs.2025.102986. PMID:
41276162. Review. ˍ
Cvitković J, Tan WL, Jiang T, Zhao Z.
Glioma
tumor microenvironment and immunotherapy: past, present, and
future.
Biomark
Res. 2025 Nov 21;13(1):150. doi:
10.1186/s40364-025-00863-2. PMID:
41272822. Review. ˍ
Mignone C, Khuong-Quang DA.
Diffuse
Pediatric High Grade Gliomas.
Neuroimaging
Clin N Am. 2025 Nov 21;36(1):35-51. doi:
10.1016/j.nic.2025.09.004. PMID:
41274769. Review˰
ˍ
Mastronuzzi A, Franceschi E, D'Antonio F, Bennicelli E, Berzero G,
Cella E, Filippi M, Lanzetta G, Marchioni E, Milanaccio C,
Simonelli M, Bini P, Silvani A, Pace A.
Diagnostic
and predictive molecular biomarkers in brain tumors across the
lifespan: an age-stratified consensus statement.
J
Neurooncol. 2025 Nov 24;176(1):95. doi:
10.1007/s11060-025-05329-x. PMID:
41284071. Review. ˍ
Rossi J, Picca A, Santonocito OS, Schembari S, Testaverde L,
Sanson M, Berzero G, Di Stefano AL.
Advances
in the management of patients with idh-mutant glioma.
Oncologist.
2025 Nov 24:oyaf391. doi:
10.1093/oncolo/oyaf391. PMID:
41284931. Review. ˍ
Xu D, He L, Zhao X, Yang Z.
Bibliometric
evaluation of research trends and hotspots concerning the
interaction between immune checkpoint inhibitors and glioma.
Discov
Oncol. 2025 Nov 24;16(1):2144. doi:
10.1007/s12672-025-04013-w. PMID:
41284174. Bibliometric analysis. ˍ
Daher A, Jaber MY, Maraka S, Vemaganti H, Valyi-Nagy T.
Extraneural Metastasis in
Oligodendroglioma: A Comprehensive Review and Outcome Analysis of
90 Cases.
Cancer
Sci. 2025 Nov 27. doi:
10.1111/cas.70275. PMID:
41310947. Review. ˍ
Vargas LO, Himic V, Otaner F, Abikenari M, Chandar J, Govindarajan
V, Kreatsoulas D, Jahangiri A, Komotar RJ, Ivan ME, Shah AH.
Modulating the glioma microenvironment
with laser interstitial thermal therapy: mechanisms and
therapeutic implications.
J
Neurooncol. 2025 Nov 27;176(1):99. doi:
10.1007/s11060-025-05305-5. PMID:
41307758. Review. ˍ
Zagozewski J, Haldipur P, Millen KJ, Werbowetski-Ogilvie TE.
Medulloblastoma stem cell programs:
Molecular roadmaps of disease progression.
Dev
Cell. 2025 Nov 27:S1534-5807(25)00692-6. doi:
10.1016/j.devcel.2025.10.018. PMID:
41314219. Review. ˍ
Jadhav A, J A, Patel T.
A
comprehensive review redefining viruses as therapeutic agents in
cancer treatment.
Discov
Oncol. 2025 Nov 28. doi:
10.1007/s12672-025-03973-3. PMID:
41313526. Review. ˍ
Soumbasis A, Ueno A, Elliott D, Lama S, Edwards S, Starreveld YP,
Zhang Y, Federico P, Sutherland GR, LeVan P, Poon CC.
The
glymphatic system and glioblastoma.
Brain.
2025 Nov 28:awaf449. doi:
10.1093/brain/awaf449. PMID:
41310975. Review. ˍ
Oztek MA, Wright JN.
Central Nervous
System Embryonal Tumors.
Neuroimaging
Clin N Am. 2025 Oct 7;36(1):85-106. doi:
10.1016/j.nic.2025.08.007. PMID:
41274772. Review˰
ˍ
Powers AM, Neuberger I.
Pediatric
Diffuse Low-Grade Gliomas: Radiology, Symptoms, Treatment, and
Molecular Pathways.
Neuroimaging
Clin N Am. 2025 Oct 7;36(1):23-34. doi:
10.1016/j.nic.2025.08.006. PMID:
41274768. Review˰
ˍ
Haile H, Leskinen S, Adapa AR, R Goldberg A, Viswanathan A,
Milligan C, Conboy K, Schevon C, Canoll P, Gill BJA.
The
Role of mTOR Signaling in Tumor-Induced Alterations to Neuronal
Function in Diffusely Infiltrating Glioma.
Biomedicines.
2025 Oct 23;13(11):2593. doi:
10.3390/biomedicines13112593. PMID:
41301687. Review. ˍ
Thomas AG, Chattopadhyay A, Dineen RA.
Ependymal
Tumors.
Neuroimaging
Clin N Am. 2025 Oct 23;36(1):69-83. doi:
10.1016/j.nic.2025.08.008. PMID:
41274771. Review˰
ˍ
Mishra J, Dickinson JD, Maurya SK.
Brain
microenvironment orchestrates highly aggressive tumor variants:
current trends and therapeutic approaches.
Front
Aging Neurosci. 2025 Nov 5;17:1666837. doi:
10.3389/fnagi.2025.1666837. PMID:
41268299. Review. ˍ
Durga YK, Pusapati RV.
Drug resistance
in glioblastoma: Challenges, mechanisms and therapeutic strategies
(Review).
Mol
Clin Oncol. 2025 Nov 6;24(1):4. doi:
10.3892/mco.2025.2913. PMID:
41281928. Review. ˍ
Adefolaju A, Kram DE, Mann B, Hingtgen S, Satterlee A.
Informing
development of brain cancer therapies within "preclinical
trials" using ex vivo patient tumors.
Adv
Drug Deliv Rev. 2025 Nov 19;228:115736. doi:
10.1016/j.addr.2025.115736. PMID:
41270976. Review. ˍ